TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $105 to $130.
TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $105 to $130.